WO1997019185A1 - Production of optically active 2-substituted tetrahydropyran-4-ones - Google Patents

Production of optically active 2-substituted tetrahydropyran-4-ones Download PDF

Info

Publication number
WO1997019185A1
WO1997019185A1 PCT/GB1996/002838 GB9602838W WO9719185A1 WO 1997019185 A1 WO1997019185 A1 WO 1997019185A1 GB 9602838 W GB9602838 W GB 9602838W WO 9719185 A1 WO9719185 A1 WO 9719185A1
Authority
WO
WIPO (PCT)
Prior art keywords
ester
stereospecific
alcohol
stereospecifically
substituted
Prior art date
Application number
PCT/GB1996/002838
Other languages
French (fr)
Inventor
Robert Antony Holt
Stuart Richard Rigby
David Waterson
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Limited filed Critical Zeneca Limited
Priority to AU75836/96A priority Critical patent/AU7583696A/en
Priority to US09/077,192 priority patent/US5962282A/en
Priority to EP96938390A priority patent/EP0862646B1/en
Priority to JP9519488A priority patent/JP2000500344A/en
Priority to DK96938390T priority patent/DK0862646T3/en
Priority to AT96938390T priority patent/ATE215603T1/en
Priority to DE69620437T priority patent/DE69620437T2/en
Publication of WO1997019185A1 publication Critical patent/WO1997019185A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02Oxygen as only ring hetero atoms
    • C12P17/06Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction

Definitions

  • THIS INVENTION relates to a Process for the Production of Optically Active 2-Subst ⁇ tuted tetrahydropyran-4-ones.
  • Certain tetrahydropyran-4-ones are of interest as chemical intermediates in the production of biologically active materials, for example those of European Patents 465,812; 462,813; 409,413; 420,511; 410,661; 385,662 and 375,404.
  • compounds of enhanced activity are produced if the tetrahydropyran-4- one is 2-subst ⁇ tuted and is m the (S) configuration.
  • Compounds of the (R) configuration are of possible research interest.
  • This invention comprises a process of producing an optically active 2-substituted tetrahydropyran-4-ol or ester thereof which comprises stereospecifically esterifying a 2-subst ⁇ tuted tetrahydropyran-4-ol using a stereospecific esterase or stereospecifically hydrolysing an ester thereof with a stereospecific hydrolase.
  • the hydrolysis of the ester product may be carried out using a stereospecific hydrolase in order to increase the optical purity further.
  • the racemic mixture of the 2-subst ⁇ tuted tetra- hydropyran-4-ol m substantially the cis form may be produced by reacting but-3-ene-l ol with an aldehyde of formula X CHO in which X is the desired 2-substituent of the pyranol in the presence of an acid which is preferably sulphuric acid.
  • X is suitably an alkyl for example, an ethyl or methyl group or a substituted alkyl for example mono or di fluoro-substituted alkyl for example methyl or ethyl group.
  • the invention also comprises a process of producing an optically active 2-subst ⁇ tuted tetrahydropyran-4-ol or ester thereof which comprises producing a cis-racemic 2- substituted tetrahydopyran-4 or by reacting but -3-ene- l-ol with an aldehyde of formula XCHO in which X is the desired 2-substituent of the pyranol in the presence of an acid, esterifying the racemic mixture using a stereospecific esterase or esterifying the racemic mixture optionally non stereospecifically and hydrolysing it with a stereospecific hydrolase.
  • the esters may be made by normal methods, preferably using the free acids, acyl halides and/or anhydrides, m non stereospecific esterification In stereospecific esterification it is preferred to transeste ⁇ fy with another ester, which is suitably a vinyl ester, as the by-product, acetaldehyde, is not involved in a back- reaction.
  • stereospecific esterification it is preferred to transeste ⁇ fy with another ester, which is suitably a vinyl ester, as the by-product, acetaldehyde, is not involved in a back- reaction.
  • the stereospecific esterification reaction and/or hydrolysis be carried out at a pH of 5 to 10, at least if excess water for example watei of reaction, is present, more preferably 6 to 9, and a temperature of preferably 20 to 65°C, more preferably 25 to 50°C
  • the esters are preferably esters of lower alkanoic acids having 2 to 8 carbon atoms, benzoic acid or substituted derivatives thereof.
  • the enzymes may be provided as such or as whole cells comprising them. It is preferred that they be immobilised so as to facilitate their separation from the product and, if desired, re-use.
  • the stereospecific esterification and/or hydrolysis step(s) may be carried out by mixing the reactant (s) with the enzyme, normally in the presence of at least an amount of water sufficient to allow enzyme activity and, in the case of hydrolysis to supply the water of reaction and optionally an inert solvent.
  • Preferred enzymes include those from Humicola lanuginosa for example that sold under the Trade Mark Lipolase and Pseudomonas for example that sold under the Trade Mark SAM II and more preferably those from Candida antarctica, for example that sold under the Trade Mark NOVOZYM.
  • Oxidation of the alcohol to the ketone is suitably carried out with a strong oxidising agent, for example chromic acid suitably in the presence of a strong acid for example sulphuric acid and an inert organic solvent for example a ketone.
  • a strong oxidising agent for example chromic acid suitably in the presence of a strong acid for example sulphuric acid and an inert organic solvent for example a ketone.
  • the temperature is preferably in the range 0 to 40°C for example 0 to 30°C
  • the alcohol may be further reacted, for example by oxidation of the corresponding ketone m the presence of the ester. Any separation of the ester which is required may be carried out after such further reaction
  • the invention may be used as a route to either the product of the stereospecific reaction or to the unconverted lsosmer EXAMPLE 1
  • Racemic c ⁇ s-2-methyltetrahydro- (4H) -pyran-4-ol was prepared by the method of E Hanschke (Chemische Be ⁇ chte (1955), volume 88, p 1053).
  • esterification was carried out as follows A solution of c ⁇ s-2-methyltetrahydro- (4H) -pyran-4-ol (20g, 0.172 mole) and triethylamine (20.2g, 0.20 mole) m dichloromethane (120ml) was cooled in an ice bath Butyryl chloride (18.1g, 0.17 mole) was added slowly with stirring over 15 minutes The ice bath was removed and the reaction stirred at room temperature for 3 hours Water (100ml) was added to the reaction mixture and the organic fraction recovered from the mixture The organic phase was washed with dilute hydrochloric acid (75ml, 2 molar), saturated aqueous sodium chloride (75ml) and then dried over anhydrous magnesium sulphate. The solvent was removed under reduced pressure. The residue was distilled under reduced pressure to yield the butyrate ester (20.g, 64% yield, 60-73°C/5mm Hg) The product contained approximately 5% of the trans isomer.
  • the enzymic hydrolysis of esters was carried out m a Mettler DL25 autotitrator to maintain the pH at the desired level.
  • the extent of hydrolysis was conveniently calculated from the consumption of the titrant, sodium hydroxide.
  • the enantiomers of the butyric ester were measured by HPLC using a Chiralcel OB column, 250mm x 4.6mm (Daicel Chemical Industries Ltd) eluted with hexane : 2- propanol (99:1) at a rate of lml/minute.
  • the ester was detected by UV absorption at 215nm. Under these conditions the (2S, 4S) butyric ester eluted at 5.7 minutes whilst the (2R, 4R) butyric ester eluted at 7.2 minutes.
  • the results of the enzyme screen are shown in Table 1.
  • the pH was controlled at pH 7.8-8.0 by the automatic addition of sodium hydroxide solution (5 molar) , the temperature was controlled at 28- 32°C.
  • the reaction mixture was filtered through a Whatman GF/B glass fibre filter to remove the enzyme beads. The filtrate was allowed to settle and the upper organic layer recovered. Pentane (500ml) was added to the organic fraction which was then washed twice with deionised water (1 litre) to remove traces of pyranol from the organic fraction. The separated organic fraction was dried over anhydrous sodium sulphate and filtered.
  • the temperature programme consisted of an initial 1 minute at 100°C followed by an increase to 170°C at a rate of 20°C/minute, the temperature was then maintained at 170°C for 10 minutes.
  • the retention time of c ⁇ s-2-methyl- tetrahydro- (4H) -pyran-4-ol was 6.1 minutes whilst that for the correspondmg butyrate ester was 12.1 mmutes.
  • the rate of reaction decreased as it approached 50% esterification and the reaction stopped after 12 hours at 52.5% esterification.
  • the solution was filtered to remove the enzyme beads and then the filtrate was extracted twice with an equal volume of water to remove unreacted cis-2-methyl ⁇ tetrahydro- (4H) -pyran-4-ol .
  • the combined aqueous extracts were then back-extracted twice with an equal volume of pentane to remove any trace of butyrate ester from the aqueous phase.
  • the aqueous solution containing the c ⁇ s-2-methyltetrahydro- (4H) -pyran-4-ol was then saturated with sodium chloride and extracted twice with an equal volume of ethyl acetate.
  • the ethyl acetate extract was dried over anhydrous sodium sulphate and the solvent removed by distillation under reduced pressure to yield resolved c ⁇ s-2-methyltetrahydro- (4H) -pyran-4-ol (8.86g) .
  • the enantiomeric purity of the resolved c ⁇ s-2- methyltetrahydro- (4H) -pyran-4-ol was determmed by chiral stationary phase HPLC of the benzoyl ester.
  • the benzoyl ester was synthesised as follows; To a 50ml stoppered tube was added cis-2-methyltetrahydro- (4H) -pyran-4-ol (0.2g, 1.724m mole), benzoic anhydride (0.39g, 1.725m mole) , pyridine (5ml) and dimethylaminopyridine (5mg) . The mixture was incubated at 60°C for 6 hours.
  • the reaction mixture was cooled to room temperature, diluted to 50ml with diethylether and washed successively with 2 x 50ml hydrochloric acid (20 millimolar) , sodium hydroxide (100 millimolar) , distilled water and saturated aqueous sodium chloride.
  • the organic layer was recovered, dried over anhydrous sodium sulphate and filtered.
  • the filtrate was collected and the diethyl ether removed by distillation under reduced pressure to yield the benzoyl ester of cis-2-methyltetrahydro- (4H) - pyran-4-ol as a pale yellow oil.
  • the enantiomeric purity was determined using a Chiralcel OB column (Daicel Chemical Industries Ltd) , 250mm x 4.6mm, eluted with hexane : ethanol (99.5 0.5) at a rate of 0.75ml/m ute.
  • the compounds were detected by UV absorption at 225mm.
  • the retention times for the (2R, 4R) and (2S, 4S) enantiomers of the benzoyl ester derivative of 2-methyltetrahydro- (4H) -pyran-4-ol were 17.1 minutes and 21.7 mmutes respectively. Analysis of the resolved sample indicated the optical purity to be 98.5% (2S, 4S) , 1 5% (2R, 4R) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Optically active 2-substituted tetrahydropyran-4-ols or esters thereof may be prepared using esterases or hydrolases from the corresponding racemic mixtures of esters or alcohols. This provides a route to the corresponding optically active ketones. The racemic mixtures are preferably in the cis-form. Such mixtures may be produced by reacting but-3-ene-1-ol with an aldehyde in the presence of an acid.

Description

Production of Optically Active 2-Substituted Tetrahydropyran-4-ones
THIS INVENTION relates to a Process for the Production of Optically Active 2-Substιtuted tetrahydropyran-4-ones.
Certain tetrahydropyran-4-ones are of interest as chemical intermediates in the production of biologically active materials, for example those of European Patents 465,812; 462,813; 409,413; 420,511; 410,661; 385,662 and 375,404. In at least some cases compounds of enhanced activity are produced if the tetrahydropyran-4- one is 2-substιtuted and is m the (S) configuration. Compounds of the (R) configuration are are of possible research interest. This invention comprises a process of producing an optically active 2-substituted tetrahydropyran-4-ol or ester thereof which comprises stereospecifically esterifying a 2-substιtuted tetrahydropyran-4-ol using a stereospecific esterase or stereospecifically hydrolysing an ester thereof with a stereospecific hydrolase.
We have found that the invention may be carried out with surprisingly high stereo specificity.
If desired the hydrolysis of the ester product may be carried out using a stereospecific hydrolase in order to increase the optical purity further.
The cis 2-subst tuted tetrahydropyran-4-ols or esters react more readily m the invention than the trans compounds and the (R) compounds can be reacted stereospecifically both in esterification and hydrolysis thereby leaving the (S) compounds unconverted.
The racemic mixture of the 2-substιtuted tetra- hydropyran-4-ol m substantially the cis form may be produced by reacting but-3-ene-l ol with an aldehyde of formula X CHO in which X is the desired 2-substituent of the pyranol in the presence of an acid which is preferably sulphuric acid. X is suitably an alkyl for example, an ethyl or methyl group or a substituted alkyl for example mono or di fluoro-substituted alkyl for example methyl or ethyl group. A method for this process using H2S04 as catalyst is described by Hanschke (Chem Ber (1955) vol 88 p 1053) . Cis and trans orientations are lost on oxidation to the corresponding ketone but we have found the cis product to be very suitable for this invention.
The invention also comprises a process of producing an optically active 2-substιtuted tetrahydropyran-4-ol or ester thereof which comprises producing a cis-racemic 2- substituted tetrahydopyran-4 or by reacting but -3-ene- l-ol with an aldehyde of formula XCHO in which X is the desired 2-substituent of the pyranol in the presence of an acid, esterifying the racemic mixture using a stereospecific esterase or esterifying the racemic mixture optionally non stereospecifically and hydrolysing it with a stereospecific hydrolase.
The esters may be made by normal methods, preferably using the free acids, acyl halides and/or anhydrides, m non stereospecific esterification In stereospecific esterification it is preferred to transesteπfy with another ester, which is suitably a vinyl ester, as the by-product, acetaldehyde, is not involved in a back- reaction. It is preferred that the stereospecific esterification reaction and/or hydrolysis be carried out at a pH of 5 to 10, at least if excess water for example watei of reaction, is present, more preferably 6 to 9, and a temperature of preferably 20 to 65°C, more preferably 25 to 50°C The esters are preferably esters of lower alkanoic acids having 2 to 8 carbon atoms, benzoic acid or substituted derivatives thereof.
The enzymes may be provided as such or as whole cells comprising them. It is preferred that they be immobilised so as to facilitate their separation from the product and, if desired, re-use.
The stereospecific esterification and/or hydrolysis step(s) may be carried out by mixing the reactant (s) with the enzyme, normally in the presence of at least an amount of water sufficient to allow enzyme activity and, in the case of hydrolysis to supply the water of reaction and optionally an inert solvent.
Preferred enzymes include those from Humicola lanuginosa for example that sold under the Trade Mark Lipolase and Pseudomonas for example that sold under the Trade Mark SAM II and more preferably those from Candida antarctica, for example that sold under the Trade Mark NOVOZYM.
Oxidation of the alcohol to the ketone is suitably carried out with a strong oxidising agent, for example chromic acid suitably in the presence of a strong acid for example sulphuric acid and an inert organic solvent for example a ketone. The temperature is preferably in the range 0 to 40°C for example 0 to 30°C
If desired, the alcohol may be further reacted, for example by oxidation of the corresponding ketone m the presence of the ester. Any separation of the ester which is required may be carried out after such further reaction The invention may be used as a route to either the product of the stereospecific reaction or to the unconverted lsosmer EXAMPLE 1
Preparation of Racemic Cis-2-Mβthyltetrahydro- (4H)-Pyran- 4-ol Butyrate Ester
Racemic cιs-2-methyltetrahydro- (4H) -pyran-4-ol was prepared by the method of E Hanschke (Chemische Beπchte (1955), volume 88, p 1053).
Typically esterification was carried out as follows A solution of cιs-2-methyltetrahydro- (4H) -pyran-4-ol (20g, 0.172 mole) and triethylamine (20.2g, 0.20 mole) m dichloromethane (120ml) was cooled in an ice bath Butyryl chloride (18.1g, 0.17 mole) was added slowly with stirring over 15 minutes The ice bath was removed and the reaction stirred at room temperature for 3 hours Water (100ml) was added to the reaction mixture and the organic fraction recovered from the mixture The organic phase was washed with dilute hydrochloric acid (75ml, 2 molar), saturated aqueous sodium chloride (75ml) and then dried over anhydrous magnesium sulphate. The solvent was removed under reduced pressure. The residue was distilled under reduced pressure to yield the butyrate ester (20.g, 64% yield, 60-73°C/5mm Hg) The product contained approximately 5% of the trans isomer.
NMR (CDClj) . 0.95 (3H, m) , 1.15-2 05 (9H, m) , 2.30 (2H, m) , 3.45 (2H, m) , 4.0 (IH, m) , 4.85 (IH, m) . EXAMPLE 2
Identification of Enzymes Hydrolysing Cis-2-Methyl- tetrahydro-(4H) -Pyran-4-ol Esters Enantioselectivβly
The enzymic hydrolysis of esters was carried out m a Mettler DL25 autotitrator to maintain the pH at the desired level. The extent of hydrolysis was conveniently calculated from the consumption of the titrant, sodium hydroxide.
The butyric ester (0.29g) waε suspended as droplets in a buffer (30ml) of pH 7.5 comprising tris
(hydroxymethyl) ammo methane (lOmM), sodium chloride (60mM) and calcium chloride (20mM) . To this was added enzyme (lOOmg of solid or 2ml when a liquid). The temperature was held at 30°C and the reaction mixture stirred whilst pH was maintained by the automatic addition of aqueous sodium hydroxide (0.25 molar) . A decrease m titration rate as hydrolysis approached 50% was used as an indication of enantioselectivity, promising reactions were extracted and analysed as follows. When the quantity of sodium hydroxide added was equivalent to the hydrolysis of 50% of the ester the reaction mixture was extracted with an equal volume of diethyl ether. Where immobilised enzyme was used this was removed by filtration prior to extraction with diethyl ether. The residual ester was recovered m the ether layer whilst the enzyme and the majority of the pyranol were present in the aqueous layer. The ether layer was washed with an equal volume of water to remove traces of pyranol from the organic layer. The diethyl ether fraction was dried over anhydrous sodium sulphate, the ether layer recovered by filtration and the butyric ester isolated from it by removal of the ether by distillation at reduced pressure.
The enantiomers of the butyric ester were measured by HPLC using a Chiralcel OB column, 250mm x 4.6mm (Daicel Chemical Industries Ltd) eluted with hexane : 2- propanol (99:1) at a rate of lml/minute. The ester was detected by UV absorption at 215nm. Under these conditions the (2S, 4S) butyric ester eluted at 5.7 minutes whilst the (2R, 4R) butyric ester eluted at 7.2 minutes. The results of the enzyme screen are shown in Table 1.
TABLE 1
Enzyme Source Hydrolysis Ratio of Butyric Ester
Enantiomers (S) : (R)
Chromobacterium B Yes nd viscosum
Pseudomonas B Yes nd fluorescens
Mucor miehei B No nd
Geotrichum candidum B No nd
Candida cylindracea B Yes nd
Porcine pancreatic B No nd lipase
Porcine liver S Yes nd esterase
Lipase P A Yes 80 : 20
Lipase SAM II A Yes 80 : 20
Lipolase ™ N Yes > 95 : 5
Novozym 435 ™ N Yes > 95 : 5
nd not determined. B Biocatalysts Ltd, Main Avenue, Treforest Industrial Estate, Pontypridd CF37 5UT, United Kingdom. S Sigma Chemical, Fancy Road, Poole, Dorset BH17 7BR,
United Kingdom. A Amano Pharmaceutical Co Ltd, Eschersheimer Landstrasse 49, D-6000, Frankfurt am Ma 1,
Germany. N Novo Nordisk A/S, Novo alle, 2880 Bagsvaerd, Denmark. EXAMPLE 3
Preparative Scale Resolution of 2-Methyltetrahydro- (4H)- Pyran-4-ol Butyrate Ester using Lipase from Candida Antarctica (NOVOZYM 435™) and conversion to (S)-2- Methyltetrahydro-(4H)-Pyran-4-one
To a 10 litre stirred glass reaction vessel was added water (4 litres) and tris (hydroxymethyl) amino methane free base (4.84g, 40 millimoles) to give a solution of pH 9.5. To this was added 2-methyl- tetrahydro- (4H) -pyran-4-ol butyrate ester (2.933Kg, 15.77 moles) resulting in a decrease in pH to 5.0. The pH of the stirred biphasic mixture was adjusted to pH 8.0 with sodium hydroxide (5 molar) . Enzyme (30g of Novozym 435™ beads) was slurried in 100ml of water and added to the reactor to start the reaction. The pH was controlled at pH 7.8-8.0 by the automatic addition of sodium hydroxide solution (5 molar) , the temperature was controlled at 28- 32°C. After 25 hours the reaction mixture was filtered through a Whatman GF/B glass fibre filter to remove the enzyme beads. The filtrate was allowed to settle and the upper organic layer recovered. Pentane (500ml) was added to the organic fraction which was then washed twice with deionised water (1 litre) to remove traces of pyranol from the organic fraction. The separated organic fraction was dried over anhydrous sodium sulphate and filtered. The filtrate was then distilled at reduced pressure to remove pentane yielding resolved (4S, 6S)-2- methyltetrahydro- (4H) -pyran-4-ol butyrate ester as a pale yellow oil. Ester recovered = 1.359Kg (46% yield, 96% chemical strength) .
A sample of the resolved 2-methyltetrahydro- (4H) - pyran-4-ol butyrate ester was hydrolysed to the corresponding alcohol as follows. Butyrate ester (627.8g, 96% chemical strength) was added to a solution of sodium hydroxide (5 molar, 1200ml) and the mixture warmed to 70°C. After 1.5 hours the mixture was cooled to room temperature and saturated aqueous sodium chloride (600ml) was added. The mixture was extracted with diethyl ether (600ml x 11) . The organic fractions were combined and dried over anhydrous magnesium sulphate, decolourised with charcoal and the solvent removed under reduced pressure to yield 2-methyltetrahydro- (4H) -pyran- 4-ol (353. lg, 94% yield) . NMR (CDClj) : 1.21 (3H, d) , 1.5 (2H, m) , 1.9 (2H, m) , 3.4 (2H, m) , 3.78 (IH, m) , 4.0 (IH, m) .
A sample of the 2-methyltetrahydro- (4H) -pyran-4-ol was oxidised to 2-methyltetrahydro- (4H) -pyran-4-one under the following conditions. 2-methyltetrahydro- (4H) -pyran- 4-ol (119g) was added to acetone (2700ml) and cooled to 8°C on an ice bath. Chromic acid solution (234ml, 8N - prepared by adding 266.7g of chromium (VI) oxide to a mixture of 230ml of concentrated sulphuric acid and 400ml of water and made up to 1 litre with water) was added dropwise over 1 hour with rapid stirring. After a further 2 hours isopropanol (5ml) was added gradually until the colour of the solution turned green. The acetone solution was decanted and filtered. The residue was washed with acetone. The combined filtrate and washings were distilled under reduced pressure to remove acetone, the aqueous residue was then extracted with diethyl ether (500ml followed by 3 x 125ml) . The combined extracts were dried over magnesium sulphate and the diethyl ether removed under reduced pressure. The residue was distilled under reduced pressure to yield the pyranone (92.4g, 79%, 60°C/80mm Hg) . NMR (CDC13) : 1.31 (3H, d) , 2.2-2.64 (4H, m) , 3.69 (2H, m) , 4.28 (IH, m) .
The enantiomeric purity of 2-methyltetrahydro- (4H) - pyran-4-one was determined by chiral stationary phase HPLC using the conditions described in Example 2. The (S) -enantiomer eluted at 15.6 minutes whilst the (R) - enantiomer eluted at 18.1 minutes. The reaction product consisted of 98% (S) -enantiomer, 2% (R) -enantiomer.
EXAMPLE 4
Resolution of Racemic Cis-2-Methyltetrahydro-(4H) -Pyran- 4-ol by Enantioselective Transesterification Catalysed by NOVOZYM 435™ in the presence of Vinyl Butyrate
To 20g of racemic cis-2-methyltetrahydro- (4H) -pyran- 4-ol (0.172 mole) was added vinyl butyrate (14g, 0.123 mole) and Novozym 435™ immobilised enzyme preparation (0.2g) . The reaction mixture was stirred at 28°C. The reaction was monitored for formation of butyrate ester and disappearance of pyranol by gas chromatography. Analysis was carried out using a Perkin-Elmer 8500 gas chromatograph fitted with a 30 metre x 0.32mm DB5 column (J & W Scientific) . Helium (8psι) was the carrier gas and detection was by flame ionisation. The temperature programme consisted of an initial 1 minute at 100°C followed by an increase to 170°C at a rate of 20°C/minute, the temperature was then maintained at 170°C for 10 minutes. The retention time of cιs-2-methyl- tetrahydro- (4H) -pyran-4-ol was 6.1 minutes whilst that for the correspondmg butyrate ester was 12.1 mmutes. The rate of reaction decreased as it approached 50% esterification and the reaction stopped after 12 hours at 52.5% esterification. The solution was filtered to remove the enzyme beads and then the filtrate was extracted twice with an equal volume of water to remove unreacted cis-2-methyl¬ tetrahydro- (4H) -pyran-4-ol . The combined aqueous extracts were then back-extracted twice with an equal volume of pentane to remove any trace of butyrate ester from the aqueous phase. The aqueous solution containing the cιs-2-methyltetrahydro- (4H) -pyran-4-ol was then saturated with sodium chloride and extracted twice with an equal volume of ethyl acetate. The ethyl acetate extract was dried over anhydrous sodium sulphate and the solvent removed by distillation under reduced pressure to yield resolved cιs-2-methyltetrahydro- (4H) -pyran-4-ol (8.86g) .
The enantiomeric purity of the resolved cιs-2- methyltetrahydro- (4H) -pyran-4-ol was determmed by chiral stationary phase HPLC of the benzoyl ester. The benzoyl ester was synthesised as follows; To a 50ml stoppered tube was added cis-2-methyltetrahydro- (4H) -pyran-4-ol (0.2g, 1.724m mole), benzoic anhydride (0.39g, 1.725m mole) , pyridine (5ml) and dimethylaminopyridine (5mg) . The mixture was incubated at 60°C for 6 hours. The reaction mixture was cooled to room temperature, diluted to 50ml with diethylether and washed successively with 2 x 50ml hydrochloric acid (20 millimolar) , sodium hydroxide (100 millimolar) , distilled water and saturated aqueous sodium chloride. The organic layer was recovered, dried over anhydrous sodium sulphate and filtered. The filtrate was collected and the diethyl ether removed by distillation under reduced pressure to yield the benzoyl ester of cis-2-methyltetrahydro- (4H) - pyran-4-ol as a pale yellow oil.
The enantiomeric purity was determined using a Chiralcel OB column (Daicel Chemical Industries Ltd) , 250mm x 4.6mm, eluted with hexane : ethanol (99.5 0.5) at a rate of 0.75ml/m ute. The compounds were detected by UV absorption at 225mm. The retention times for the (2R, 4R) and (2S, 4S) enantiomers of the benzoyl ester derivative of 2-methyltetrahydro- (4H) -pyran-4-ol were 17.1 minutes and 21.7 mmutes respectively. Analysis of the resolved sample indicated the optical purity to be 98.5% (2S, 4S) , 1 5% (2R, 4R) . EXAMPLE 5
Resolution of Racemic Cis-2-Methyltetrahydro-(4H)-Pyran- 4-ol by Enantioselective Transesterification Catalysed by NOVOZYM 435™ in the presence of Vinyl Acetate To 2g of racemic cis-2-methyltetrahydro- (4H) -pyran-
4-ol (17.2 millimoles) was added l.Olg of vmyl acetate (12.9 millimoles) and O.lg of immobilised enzyme preparation Novozym 435™. The reaction mixture was stirred at 28°C and the reaction monitored by gas chromatography as described Example 4. The retention time of the acetyl ester of cis-2-methyltetrahydro- (4H) - pyran-4-ol was 8.2 m utes. The reaction was halted when 58% of the pyranol had been converted to the acetyl ester (4 hours) The reaction mixture was processed as described m Example 4 to yield 0 57g of resolved cιs-2- methyltetrahydro- (4H) -pyran-4-ol The benzoyl ester derivative was prepared as Example 4 and analysed by chiral stationary phase HPLC also as described m Example 4. Analysis of the resolved sample indicated the optical purity to be 99% (2S, 4S) , 1% (2R, 4R) .

Claims

1 A process of producing an optically active 2- substituted tetrahydropyran-4-ol or ester thereof which comprises stereospecifically esterifying a 2- substituted tetrahydropyran-4-ol using a stereospecific esterase or stereospecifically hydrolysing an ester thereof with a stereospecific hydrolase.
2 A process of producing an optically active 2- substituted tetrahydropyran-4-one which comprises stereospecifically esterifying a 2-substituted tetrahydropyran-4-ol using a stereospecific esterase or stereospecifically hydrolysing an ester thereof with a stereospecific hydrolase, and oxidising the alcohol product to the corresponding ketone preferably after separating it from the ester and/or separating the ester and alcohol or ketone products hydrolysing the ester to the corresponding alcohol and oxidising the resulting alcohol to the corresponding ketone.
3 A process of producing an optically active 2- substituted tetrahydropyran-4-ol or ester thereof which comprises producing a cis-racemic 2- substituted tetrahydopyran-4-ol by reacting but -3- ene- l-ol with an aldehyde of formula XCHO in which X is the desired 2-substituent of the pyranol in the presence of an acid, esterifying the racemic mixture using a stereospecific esterase or esterifying the racemic mixture optionally non stereospecifically and hydrolysing it with a stereospecific hydrolase.
4 A process of producing an optically active 2 - substituted tetrahydropyran-4-one which comprises producing a cis-racemic 2-substituted tetrahydopyran-4-ol by reacting but -3-ene- l-ol with an aldehyde of formula XCHO m which X is the desired 2-substituent of the pyranol in the presence of an acid, esterifying the racemic mixture using a stereospecific esterase or esterifying the racemic mixture optionally non stereospecifically and hydrolysing it with a stereospecific hydrolase and oxidising the resulting alcohol or an alcohol derived from the resulting ester to the corresponding ketone by hydrolysis. A process as claimed in Claim 1 3 or 4 in which the ester is separated from the alcohol. A process as claimed in any of Claims 1 to 4 in which the alcohol is further reacted to a desired product in the presence of the ester. A process as claimed in any of Claims 1 to 5 which if the alcohol stereoisomer is required as the ester it is esterified, optionally stereospecifically and if the ester stereoisomer is required it is hydrolysed, optionally stereospecifically. A process as claimed in any preceding claim which comprises a stereospecific esterification and a stereospecific hydrolysis. A process as claimed in any preceding claim in which the 2-substituent is an alkyl or substituted alkyl group. A process as claimed in any preceding claim which the esterification is a transesterification with a v yl ester . A process as claimed any preceding claim m which the esterification is carried out the presence of a quantity of water not substantially greater than the minimum necessary to secure the optimum ef ectiveness of the enzyme. A process as claimed m any preceding claim in which the enzyme is derived from Humicola lanug osa, Pseudomonas or Candida antarctica. A process as claimed m any preceding claim m which an alcohol is produced and converted to a ketone by reacting it with a strong oxidising agent m the presence of a strong acid and an inert organic solvent .
PCT/GB1996/002838 1995-11-23 1996-11-19 Production of optically active 2-substituted tetrahydropyran-4-ones WO1997019185A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU75836/96A AU7583696A (en) 1995-11-23 1996-11-19 Production of optically active 2-substituted tetrahydropyran-4-ones
US09/077,192 US5962282A (en) 1995-11-23 1996-11-19 Production of optically active 2-substituted tetrahydropyran-4-ones
EP96938390A EP0862646B1 (en) 1995-11-23 1996-11-19 Production of optically active 2-substituted tetrahydropyran-4-ones
JP9519488A JP2000500344A (en) 1995-11-23 1996-11-19 Process for producing optically active 2-substituted tetrahydropyran-4-ones
DK96938390T DK0862646T3 (en) 1995-11-23 1996-11-19 Preparation of Optically Active 2-Substituted Tetrahydropyran-4-Ones
AT96938390T ATE215603T1 (en) 1995-11-23 1996-11-19 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-SUBSTITUTED TETRAHYDROPYRAN-4-ONE
DE69620437T DE69620437T2 (en) 1995-11-23 1996-11-19 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-SUBSTITUTED TETRAHYDROPYRAN-4-ON

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9523924.0 1995-11-23
GBGB9523924.0A GB9523924D0 (en) 1995-11-23 1995-11-23 Production of optically active 2-substituted tetrahydropyran-4-ones

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/359,319 Division US6258574B1 (en) 1995-11-23 1999-07-23 Production of optically active 2-substituted tetrahydropyran-4-ones

Publications (1)

Publication Number Publication Date
WO1997019185A1 true WO1997019185A1 (en) 1997-05-29

Family

ID=10784307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/002838 WO1997019185A1 (en) 1995-11-23 1996-11-19 Production of optically active 2-substituted tetrahydropyran-4-ones

Country Status (12)

Country Link
US (1) US5962282A (en)
EP (1) EP0862646B1 (en)
JP (1) JP2000500344A (en)
AT (1) ATE215603T1 (en)
AU (1) AU7583696A (en)
CA (1) CA2238172A1 (en)
DE (1) DE69620437T2 (en)
DK (1) DK0862646T3 (en)
ES (1) ES2171740T3 (en)
GB (1) GB9523924D0 (en)
PT (1) PT862646E (en)
WO (1) WO1997019185A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6870059B2 (en) 2000-07-19 2005-03-22 Astrazeneca Uk Ltd. Process for the preparation of 2-(6-substituted-1,-3-dioxane-4-yl)acetic acid derivatives
US7157255B2 (en) 2000-05-09 2007-01-02 Astrazeneca Uk Limited Process for the preparation of dihydroxy esters and derivatives thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258574B1 (en) * 1995-11-23 2001-07-10 Zeneca Limited Production of optically active 2-substituted tetrahydropyran-4-ones
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006235A1 (en) * 1991-09-20 1993-04-01 Zeneca Limited Process for the preparation of enantiomerically pure 4-hydroxytetrahydro-2-pyranone derivatives
WO1993006236A1 (en) * 1991-09-20 1993-04-01 Zeneca Limited Enzymatic production of optical isomers of tetrahydropyran-2-ones
US5395766A (en) * 1991-01-11 1995-03-07 Chisso Corporation Optically active trans-2-aryl-1-cyclohexanol derivatives and a process for producing the compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395766A (en) * 1991-01-11 1995-03-07 Chisso Corporation Optically active trans-2-aryl-1-cyclohexanol derivatives and a process for producing the compounds
WO1993006235A1 (en) * 1991-09-20 1993-04-01 Zeneca Limited Process for the preparation of enantiomerically pure 4-hydroxytetrahydro-2-pyranone derivatives
WO1993006236A1 (en) * 1991-09-20 1993-04-01 Zeneca Limited Enzymatic production of optical isomers of tetrahydropyran-2-ones

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157255B2 (en) 2000-05-09 2007-01-02 Astrazeneca Uk Limited Process for the preparation of dihydroxy esters and derivatives thereof
US7416865B2 (en) 2000-05-09 2008-08-26 Astrazeneca Uk Limited Process for the preparation of dihydroxy esters and derivatives thereof
US7732171B2 (en) 2000-05-09 2010-06-08 Astrazeneca Uk Limited Process for the preparation of dihydroxy esters and derivatives thereof
US7888083B2 (en) 2000-05-09 2011-02-15 Astrazeneca Uk Limited Process for the preparation of dihydroxy esters and derivatives thereof
US6870059B2 (en) 2000-07-19 2005-03-22 Astrazeneca Uk Ltd. Process for the preparation of 2-(6-substituted-1,-3-dioxane-4-yl)acetic acid derivatives
US7642363B2 (en) 2000-07-19 2010-01-05 Astrazeneca Uk Ltd. Process for the preparation of 2-(6-substituted-1,3-dioxane-4-YL) acetic acid derivatives
US7989643B2 (en) 2000-07-19 2011-08-02 Astrazeneca Uk Ltd. Process for the preparation of 2-(6-substituted-1,3-dioxane-4-yl)acetic acid derivatives

Also Published As

Publication number Publication date
AU7583696A (en) 1997-06-11
GB9523924D0 (en) 1996-01-24
ES2171740T3 (en) 2002-09-16
US5962282A (en) 1999-10-05
EP0862646A1 (en) 1998-09-09
PT862646E (en) 2002-09-30
CA2238172A1 (en) 1997-05-29
EP0862646B1 (en) 2002-04-03
DE69620437T2 (en) 2002-11-07
JP2000500344A (en) 2000-01-18
DK0862646T3 (en) 2002-07-22
ATE215603T1 (en) 2002-04-15
DE69620437D1 (en) 2002-05-08

Similar Documents

Publication Publication Date Title
EP0357009B1 (en) Method of resolution of hydroxy-cyclopentenones using a lipase and transacylation agents
US5604120A (en) Method for producing optically active endo-2-norborneols
Holmberg et al. Reaction conditions for the resolution of 2-methylalkanoic acids in esterification and hydrolysis with lipase from Candida cylindracea
KR101797799B1 (en) Process for the preparation of nebivolol
Fukusaki et al. Lipase-catalyzed kinetic resolution of methyl 4-hydroxy-5-tetradecynoate and its application to a facile synthesis of Japanese beetle pheromone
US5084392A (en) Process for producing optically active hydroxy lactones
Bianchi et al. Enzymatic resolution of 1, 2-diols: preparation of optically pure dropropizine
Sugai et al. Lipase-catalyzed kinetic resolution of 2-hydroxyhexadecanoic acid and its esters
EP0862646B1 (en) Production of optically active 2-substituted tetrahydropyran-4-ones
Kato et al. Synthesis of optically active α-monobenzoyl glycerol by asymmetric transesterification of glycerol
Benedetti et al. Synthesis of all stereoisomers of cognac lactones via microbial reduction and enzymatic resolution strategies
US4933290A (en) Process for the enzymatic separation of the optical isomers of racemic oxazolidinonic derivatives
US4923810A (en) Resolution of glycidyl esters to high enantiomeric excess
Tanaka et al. Highly asymmetric enzymatic hydrolysis and transesterification of meso-biscacetoxymethyl)-and bis (hydroxymethyl) cyclopentane derivatives: an insight into the active site model of Rhizopus Delemar lipase
Comini et al. Chemoenzymatic synthesis of enantioenriched 5-oxo-tetrahydro-3-furancarboxylic acid derivatives
US6680183B2 (en) Production of optically active 2-substituted tetrahydropyran-4-ones
Bosetti et al. Enzymatic resolution of 1, 2-diols: comparison between hydrolysis and transesterification reactions
RO112517B1 (en) Heterobicyclic alcohol pure enantiomer derivatives, manufacturing process and intermediate compounds
EP0529085B1 (en) Process for producing optically active 3-chloro-1-phenyl-1-propanol and derivative thereof
Suemune et al. Asymmetric hydrolysis of cis, cis-5-benzyloxy-1, 3-diacetoxy-cyclohexane and its application to the synthesis of chiral lactone moiety in compactin
US5231027A (en) Enzymatic process for separating the optical isomers of racemic 1,2-diols using lipase
US5254756A (en) Process for the production of (2R,3E)-4-halo-3-buten-2-ols
US5395766A (en) Optically active trans-2-aryl-1-cyclohexanol derivatives and a process for producing the compounds
IE903437A1 (en) Enantioselective enzymatic synthesis of s(-)- and¹r(+)-esters of 4-hydroxy-2-cyclopenten-1-one and its ketal¹formed with 2,2-dimethyl- propane-1,3-diol
US5272069A (en) Method of producing optically active hydroxyesters

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996938390

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2238172

Country of ref document: CA

Ref country code: CA

Ref document number: 2238172

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1997 519488

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09077192

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1996938390

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1996938390

Country of ref document: EP